RecruitingPhase 3NCT07355218
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Studying Chronic cutaneous lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Principal Investigator
- Medical ResponsibleMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Intervention
- Enpatoran(drug)
- Enrollment
- 202 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2026 – 2029
Study locations (1)
- Research Site, Darmstadt, Germany
Collaborators
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07355218 on ClinicalTrials.govOther trials for Chronic cutaneous lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980805A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Immunovant Sciences GmbH
- ENROLLING BY INVITATIONPHASE3NCT06044337A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusBiogen
- RECRUITINGPHASE1NCT06013995A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of LupusBristol-Myers Squibb